Akeso has now been advised to submit a sNDA to Chinese regulators for cadonilimab’s approval in gastric cancer by an independent data monitoring committee.

Kazia stated that in murine triple-negative breast cancer preclinical models, NDL2 reduced primary tumor volume by 49% as ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

A novel neoadjuvant therapy combining PD-1 blockade and chemoradiotherapy shows promising results in treating advanced rectal ...

Summit Therapeutics has moved ahead in the race to bring a therapy targeting both VEGF and PD- (L)1 to market, after the FDA started a review of its ivonescimab drug for lung cancer.

PD-1 checkpoint proteins on T cells (blue) can bind to two different receptors: PD-L1 and PD-L2. There are many ways to climb a mountain. This saying especially rings true in cancer research, where ...

When many cancers advance, spread and reoccur, checkpoint inhibitors can help keep difficult tumors at bay. These antibody-based immunotherapies can restore the body’s ability to recognize and ...

Abnormal expansion of PD-1+ T lymphocytes may be a sign of lupus nephritis onset in patients with SLE. Elevated PD-1+CD4+ T cells represent an independent risk factor for lupus nephritis (LN) and may ...